KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Current Deferred Revenue (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Current Deferred Revenue for 9 consecutive years, with $3.5 million as the latest value for Q3 2023.

  • On a quarterly basis, Current Deferred Revenue rose 400.0% to $3.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was $3.5 million, a 400.0% increase, with the full-year FY2022 number at $20.8 million, down 17.09% from a year prior.
  • Current Deferred Revenue was $3.5 million for Q3 2023 at Palvella Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $28.4 million in Q2 2019 to a low of $700000.0 in Q3 2022.
  • A 5-year average of $17.4 million and a median of $20.8 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: tumbled 97.35% in 2022, then surged 400.0% in 2023.
  • Palvella Therapeutics' Current Deferred Revenue stood at $11.3 million in 2019, then grew by 12.18% to $12.6 million in 2020, then surged by 98.91% to $25.1 million in 2021, then decreased by 17.09% to $20.8 million in 2022, then tumbled by 83.19% to $3.5 million in 2023.
  • Per Business Quant, the three most recent readings for PVLA's Current Deferred Revenue are $3.5 million (Q3 2023), $4.7 million (Q2 2023), and $26.7 million (Q1 2023).